Sun Boyang, Dong Yiting, Xu Jiachen, Wang Zhijie
State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences & Peking Union Medical College Beijing 100021 China.
Chronic Dis Transl Med. 2022 Mar 31;8(2):91-99. doi: 10.1002/cdt3.18. eCollection 2022 Jun.
Malignant pleural mesothelioma (MPM) is a rare and aggressive malignant disease. Currently, the platinum doublet of pemetrexed and cisplatin is the standard first-line treatment for unresectable MPM. However, recent promising results of immunotherapy have markedly changed the landscape of MPM treatment. Further, the ongoing innovative therapeutic strategies are expected to expand the range of treatment options; however, several questions remain unanswered. First, establishing predictive biomarkers with high potency is urgently needed to optimize the patient selection process. Second, further exploration of the combination algorithm is expected to unveil more effective and safe regimens. Moreover, other dilemmas, such as the resistance mechanism of immunotherapy and the role of immunotherapy in perioperative settings, still warrant further exploration.
恶性胸膜间皮瘤（MPM）是一种罕见且侵袭性强的恶性疾病。目前，培美曲塞和顺铂的铂类双联疗法是不可切除MPM的标准一线治疗方案。然而，免疫疗法最近取得的令人鼓舞的结果显著改变了MPM的治疗格局。此外，正在进行的创新治疗策略有望扩大治疗选择范围；然而，仍有几个问题尚未得到解答。首先，迫切需要建立高效的预测生物标志物以优化患者选择过程。其次，预计对联合算法的进一步探索将揭示更有效且安全的治疗方案。此外，其他难题，如免疫疗法的耐药机制以及免疫疗法在围手术期的作用，仍值得进一步探索。
